Navigation Links
Takeda to Acquire Nycomed
Date:5/18/2011

p>Tokyo (JST)

9:00 am

2:00 pm

9:00 pm

9:00 pm

10:00 pm

(May 19)

(May 19)

(May 19)

(May 19)

(May 19)Approx. Duration

60 MinutesToll-free Dial-in

Australia

Belgium

Canada

France

Germany

Hong Kong

Japan

Singapore

U.K.

U.S.A

1-800-035-017

0800-71662

1-877-855-5648

080-090-4503

0800-1802125

800-933-206

0120-917-642

800-101-1716

0800-404-9212

1-877-887-6076Direct Dial-in

Japan : +81-3-4570-1820Pass code

421299#You can also listen to the conference call via internet as following URL. (Listen only)
http://www.takeda.com/investor-information/presentations-events/index_2576.html

The conference call recording of event will be available on Takeda's website at http://www.takeda.com within several days.

About TakedaLocated in Osaka, Japan, Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Additional information about Takeda is available through its corporate website, www.Takeda.com.

About NycomedNycomed is a privately owned global pharmaceutical company with a diversified portfolio focused on branded medicines in gastroenterology, respiratory and inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC products completes the portfolio. Its R&D is structured around collaborations. In-licensing and expanding in emerging markets are cornerstones of the company's growth strategy. Nycomed emp
'/>"/>

SOURCE Takeda Pharmaceutical Company Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
2. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
3. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
4. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
5. Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
6. Takeda Initiates Two Phase III Studies with Vedolizumab (MLN0002) in Patients with Inflammatory Bowel Disease
7. Takeda to Revise Timing of Alogliptin and Alogliptin/ACTOS MAA Filings in Europe
8. Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes
9. Takeda Provides Update on the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl)
10. Takeda Initiates Cardiovascular Outcomes Trial for Alogliptin, An Investigational Treatment for Type 2 Diabetes
11. Takeda Receives FDA Complete Response Letter for the Investigational Fixed-Dose Combination of alogliptin and ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 11, 2014 According to ... Composition of Material, Application (Healthcare, Homeland security, Industrial ... (Personal Instrument, Hand-Held Instruments, Fixed, and Installed Instruments) ... 2013 - 2020", published by MarketsandMarkets, the Scintillator Market is ... from 2014 to 2020, and reach $479.16 Million ...
(Date:7/11/2014)... , July 11, 2014 According ... Research "Endoscopy Devices Market (Endoscopes, Endoscopic Operative Devices, and ... Trends and Forecast, 2013-2019" the global endoscopy devices market ... is expected to grow at a CAGR of 6.8% ... of USD 36.9 billion in 2019. Browse ...
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
Breaking Medicine Technology:Scintillator Market will be worth $479.16 Million by 2020 2Scintillator Market will be worth $479.16 Million by 2020 3Scintillator Market will be worth $479.16 Million by 2020 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 2Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 3Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 4Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 5Global Endoscopy Devices Market is Expected to Reach USD 36.9 Billion by 2019: Transparency Market Research 6Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5
... Oct. 1 FASgen,s fatty acid synthase,inhibitor (FASi) ... solid tumor xenograft cell line tested, in both ... (H460; A549; H1975; LX7); two,ovarian; breast; and, colon. ... compounds have been shown in extensive preclinical studies ...
... Show Patients with Moderate to Severe Psoriasis Who Responded to, Anti-IL-12/23 ABT-874 ... ... 24 Weeks, BUENOS AIRES, Argentina, Oct. 1 ... Abbott,s,(NYSE: ABT ) investigational anti-IL-12/23 antibody ABT-874 showed that a,majority of ...
Cached Medicine Technology:FASgen Announces Significant Milestone in Its Cancer Drug Development Program 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 2Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 3Abbott's ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study 4
(Date:7/12/2014)... 2014 The "North ... Devices Market by Angioplasty Balloon (Plain/Old, ... OCT), IVC Filter (Retrievable), Endovascular Stent ... and studies the major market drivers, ... and Canada. , Browse 108 market ...
(Date:7/12/2014)... The fastest-growing mobile technology is LTE ... of LTE networks continues to grow due to the ... have increased mobile data traffic, which is a major ... Communications Test and Measurement equipment comply with industry standards, ... Test and Measurement Market is estimated to grown from ...
(Date:7/12/2014)... injuries increase in the summer as people gather around fire ... most vulnerable to these seasonal fire hazards: children. "Young ... by putting their hands on the side of cooking grills," ... Loyola University Medical Center in Maywood, Ill., said in a ... play with fire, you get burned, is true -- ...
(Date:7/12/2014)... Using and carrying around a catheter bag can ... Va., decided that there needed to be an inconspicuous ... of our design," he said. , They then created ... an inconspicuous way to use and carry a catheter’s ... comfort and peace of mind. Producible in design variations, ...
(Date:7/12/2014)... Wright & Schulte LLC has filed a ... a subsidiary of Johnson & Johnson, on behalf of an ... receiving a metal-on-metal DePuy Pinnacle hip replacement and had to ... hip implant. The DePuy hip lawsuit was filed July 7, ... (Case No. 3:14-cv-2427) where DePuy Pinnacle Hip lawsuit litigation ...
Breaking Medicine News(10 mins):Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 2Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 3Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 4Health News:North American Interventional Cardiology & Peripheral Vascular Devices Market - New Report by MarketsandMarkets 5Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:North America Communication Test and Measurement (CT&M) Market Worth $1.9 Billion by 2018 - New Report by MicroMarket Monitor 5Health News:Burn Injuries More Common in Summer 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 2Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 3Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 4Health News:DePuy Pinnacle Hip Lawsuit Filed By Wright & Schulte LLC On Behalf of Ohio Man Who Required Revision Surgery Purportedly From Defective Hip Implant 5
... Reporter , TUESDAY, Dec. 13 (HealthDay News) -- Recreational use ... long-term changes in brain chemistry, a small, new study reveals. ... so-called "rave" drug can induce a drop in serotonin levels ... team noted, is critical to the regulation of mood, appetite, ...
... SCOTTSDALE, Ariz. Researchers at Mayo Clinic in Arizona ... have developed a vaccine that dramatically reduces tumors in ... breast and pancreatic cancer cases including those that ... described this week in the early edition of the ...
... suffering from mood and anxiety disorders such as ... more likely to abuse opioids, according to a ... Bloomberg School of Public Health. They found that mood ... opioid use. The results are featured in a recent ...
... Medical Center researchers have discovered how cholesterol-lowering drugs called ... The study was published online by the journal ... findings support a large clinical study that recently showed ... reduced their cholesterol levels but also reduced the amount ...
... Dec. 13 (HealthDay News) -- A short walk can cut ... at work, a new study suggests. U.K. researchers created ... chocolate-eaters but had gone two days without eating chocolate. They ... brisk 15-minute walk on a treadmill and then were given ...
... 13, 2011 UC Irvine researchers have uncovered an ... kidney disease, which is increasingly common due to the ... Vaziri, professor emeritus of medicine and physiology & biophysics, ... adhesive proteins, called the tight junction, that normally seal ...
Cached Medicine News:Health News:'Ecstasy' May Cause Long-Term Changes in Brain Chemistry 2Health News:'Ecstasy' May Cause Long-Term Changes in Brain Chemistry 3Health News:Scientists develop vaccine that successfully attacks breast cancer in mice 2Health News:Scientists develop vaccine that successfully attacks breast cancer in mice 3Health News:Opioid abuse linked to mood and anxiety disorders 2Health News:Opioid abuse linked to mood and anxiety disorders 3Health News:Cholesterol-lowering medication accelerates depletion of plaque in arteries 2Health News:Want to Cut Chocolate Cravings? Take a Walk 2Health News:Major cause of chronic kidney disease-related inflammation is identified 2
For implantation in proximal interphalangeal joints of the lateral toes to correct deformity associated with degenerative or rheumatoid arthritis....
Part of the GraFix® Cruciate Reconstruction System, which is designed to facilitate arthroscopic anterior cruciate ligament reconstructions....
... a new standard in the field of hammertoe ... Made of medical grade silicone, these durable and ... high level of flexibility while maintaining correct toe ... in varying stiffnesses. Lengths are determined by the ...
... Kinetik Great Toe Implant (KGTI) system offers ... of the first MPJ. The implant system ... of motion. , ,The KGTI is the ... metatarsophalangeal joint (MPJ) on the market today. ...
Medicine Products: